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Peroxynitrite-induced oxidation of plasma lipids is enhanced Over the past decade, several studies have shown that
in stable hemodialysis patients. reactive oxygen species (ROS) play a key role in the path-
Background. The relationship between end-stage renal dis- ology in a wide variety of clinical and experimental dis-ease (ESRD), hemodialysis, and oxidative stress is controver-
eases [1–4]. It is generally agreed that measurement ofsial. To determine whether ESRD causes oxidative stress, we
plasma or urinary F2-isoprostanes is the “gold standard”measured basal levels of plasma F2-isoprostanes as a marker
of lipid peroxidation in vivo, and peroxynitrite-stimulated for- for the assessment of oxidative stress in vivo [5–7]. F2-iso-
mation of F2-isoprostanes, as a marker of the oxidizibility of prostanes are isomeric forms of prostaglandin F2 formedplasma lipids in vitro, before and after routine hemodialysis.
by nonenzymatic oxidation of arachidonyl lipids. Param-Methods. Total plasma F2-isoprostanes were measured by
eters such as plasma malondialdehyde or 4-hydroxyno-gas chromatography-mass spectrometry (GC-MS) before and
after the oxidation of plasma lipids with the peroxynitrite- nenal are less reliable markers of oxidative injury in vivo
generating compound, 3-morpholino-sydnonimine (SIN-1), in [8]. The major fraction of plasma F2-isoprostanes are
23 patients with ESRD patients undergoing regular hemodialy- esterified to plasma lipids and are presumably cleaved insis, and 14 controls. Plasma vitamin E concentrations were mea-
vivo by a phospholipase to yield free F2-isoprostanes.sured by high-performance liquid chromatography (HPLC).
Thus, plasma levels of free F2-isoprostanes represent theResults. There was no difference in basal plasma concentra-
tions of F2-isoprostanes in the ESRD group prior to hemodialy- balance between the formation of esterified F2-isopros-
sis, 246  20 pg/mL, compared to controls, 252  28 pg/mL, or tanes, their subsequent hydrolysis from tissue or plasma
immediately on completion of hemodialysis, 236  14 pg/mL.
lipids, and metabolism, which may be influenced by co-Incubation of control plasma with SIN-1 caused the formation
morbid disease [9–11]. Cardiovascular disease is the mostof F2-isoprostanes with plasma concentrations increasing to
987  54 pg/mL at 6 hours. The formation of F2-isoprostanes important cause of morbidity and mortality in patients
stimulated by SIN-1 was markedly enhanced in the plasma with end-stage renal disease (ESRD) [12], and the sus-
obtained from patients undergoing hemodialysis at 1861 174 ceptibility of plasma lipids to undergo oxidative modifi-pg/mL, P 0.001, and SIN-1–induced formation of F2-isopros-
cation may be an important contributory factor. For ex-tanes was further increased in plasma obtained immediately
after hemodialysis at 2437 168 pg/mL, P 0.001. Incubation of ample, there is widespread consensus that oxidative
plasma with SIN-1 resulted in the net consumption of vitamin E. modifications of low-density lipoprotein (LDL) within
Conclusion. Although basal plasma F2-isoprostanes were sim- the arterial wall represent a key early event in the devel-ilar in patients with ESRD compared with controls, the pres-
opment of the atherosclerotic plaque. This hypothesisence of oxidative stress in patients with ESRD was unmasked
is supported by the observation that there is increasedwhen the plasma was stressed by peroxynitrite generated from
SIN-1, and this was enhanced further by hemodialysis. susceptibility of LDL to metal ion–dependent oxidation
in vitro in several groups of patients known to be at
increased risk of developing atherosclerosis [13]. ThisKey words: F2-isoprostanes, chronic renal failure, SIN-1, lipid peroxida-
tion, dialysis. method requires the isolation of the LDL fraction by
differential centrifugation in each subject, followed by
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propagation of the oxidation reaction [14]. The lag phase, (N 1). Primary renal diseases were chronic glomerulo-
nephritis (N  6), glomerulosclerosis (N  4), chronicwhich varies in duration with the antioxidant capacity
interstitial nephropathy (N 1), membranoproliferativeof LDL, is used as an index of oxidizibility of LDL. The
glomerulonephritis (N  2), diabetic nephropathy (N lag phase is shortened in patients with chronic renal
1), gouty nephropathy (N  1), chronic pyelonephritisfailure who require regular hemodialysis (ESRD) sug-
(N  3), polycystic kidney disease (N  2), or no defini-gesting increased oxidizibility of LDL [15]. This method
tive diagnosis possible (N 3). Of these 23 patients, twois, however, time consuming and does not take into ac-
were diabetic, eight patients had evidence of cardiovas-count the effect of antioxidants in whole plasma. Further-
cular, cerebrovascular, or peripheral vascular disease.more, the initiation of oxidation of LDL by metal ions
Exclusion criteria were chronic infections, including hep-is unlikely to be an important pathway in vivo. Further-
atitis C virus, any preceding acute inflammatory disease,more, the assessment of oxidative stress using other indi-
and malignancy. No patients were prescribed antioxi-ces has yielded conflicting data [8, 16–18]. In 1995, we
dants such as vitamins C or E, or fibrates. Fourteenreported that the peroxynitrite donor, 3-morpholino-
healthy controls age 50  15 years old with no clinicalsydnonimine (SIN-1), could cause the oxidation of lipids
history or signs of renal disease were recruited from thein whole plasma to form esterified F2-isoprostanes. This
same local population. No control subjects were takingwas in contrast to the inability of copper or myoglobin
any antioxidant supplements. All the healthy volunteersto induce oxidation of lipids in whole plasma. It seemed
and patients gave informed consent according to theto us that since SIN-1 could cause oxidation of plasma
guidelines of the Ethical Committee of the R. Silvestrinilipids that one could assess the oxidizibility of plasma lipids
Hospital, Perugia, Italy.by measuring the capacity of plasma components to limit
SIN-1–induced formation of F2-isoprostanes in whole Sample collection
plasma. This technique has the advantage that normal
Blood samples were collected into ethylenediamine-plasma components, which are removed during the isola-
tetraacetic acid (EDTA) tubes. Plasma was separatedtion of LDL, are still present. This technique might also
by centrifugation at 1300g for 20 minutes at 4C. Aliquotsallow the efficacy of therapeutic interventions such as
of the plasma were transferred to Eppendorf tubes andantioxidant supplementation protocols or the use of vita-
stored at 80C until analysis.min-E–coated dialysis membranes to be assessed [19].
Oxidation of plasma by SIN-1
On the day of study, 1 to 2 mL of plasma was thawed.METHODS
SIN-1 (Alexis Ltd., UK) in phosphate-buffered salineChemicals
(PBS) (pH 7.4) was added at 10% of the plasma volume
All chemicals were purchased from Sigma (Poole, to give a final concentration of 1 mmol/L SIN-1. Plasma
Dorset, UK) unless otherwise stated. and SIN-1 were incubated at 37C for 0 to 6 hours. Ali-
quots of plasma were removed (800 L at t  0, and 200Subjects
L at subsequent time points) during SIN-1 incubation.
Twenty-three stable ESRD patients (age, 62  18 Further oxidation of plasma lipids was quenched in the
years old; male  11, female  12) on regular three removed aliquots by the addition of butylated hydroxy-
times a week hemodialyis for more than 6 months were toluene (BHT) 1 mmol/L final concentration and Trolox
recruited from the Nephrology and Dialysis Unit of the dissolved in methanol 100 mol/L final concentration.
R. Silvestrini Hospital in Perugia, Italy. Patients were
well dialyzed (Kt/V 1.3) using fistula access, with stan- Extraction and measurement of F2-isoprostanes
dard bicarbonate dialysate (AAMI quality) and unfrac- Total F2-isoprostanes (esterified plus free F2-isopros-
tionated porcine heparin, using either biocompatible or tanes) were quantified by gas chromatography-mass
bioincompatible dialysis membranes. The synthetic mem- spectrometry (GC-MS) after base hydrolysis of lipids in
branes comprised polysulphone (Polysulfone Fresenius whole plasma, purification, and derivatization. In brief,
A.G., Bad Homburg, Germany) (N  5), polyamide 1 ng of [2H4]-8-iso-prostaglandin F2 (PGF2) (Cayman
(Polyflux Gambro AB, Stockholm, Sweden) (N  2), Co., Ann Arbor, MI, USA) were added as internal stan-
polymethylmethacrylate (Excebrane Serie Terumo Co., dards to 200 to 800 L of plasma containing BHT. A
Japan) (N 1), and Serie B1 (Toray Co., Japan) (N 1), half volume of 25% potassium hydroxide was added to
or polyacrylonitrile (AN69, Hospal) (N 1) membranes. plasma to give a final concentration of 8.3% potassium
The cellulosic and/or modified cellulosic membranes com- hydroxide and incubated at 37C for 45 minutes. To
prised cuprammonium rayon dialyzers (Clirans Terumo extract F2-isoprostanes, the pH was adjusted to 3, and the
Co., Japan) (N  8), and cellulose acetate (N  4), samples were extracted on a tC18 solid-phase extraction
cartridge (Waters, UK), converted to the pentafluro-or cuprammonium rayon-polyethylenglycol membranes
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Table 1. Clinical biochemistry and hematology (mean  SEM)
End-stage
renal failure Normal
(N  21) range
Total cholesterol mg/dL 20011 120–210
Triglycerides mg/dL 19725 50–170
Creatinine mg/dL 90.43 0.5–1.2
Urea mg/dL 1656.5 11–50
Hemoglobin g/dL 11.00.3 14–16.1 (M)
11.5–16.5 (F)
Hematocrit % 330.8 36–54
Fig. 1. Time-course of whole plasma lipid oxidation as measured bybenzyl ester, purified by thin-layer chromatography and F2-isoprostane generation after addition of 1 mmol/L 3-morpholino-
analyzed as the trimethysilyl ether as previously de- sydnonimine (SIN-1). Further details on this in vitro test are given in
the Methods section. Data are mean SEM. Symbols are: (), patientsscribed [20]. Detection was performed by selected ion
with end-stage renal disease (ESRD) (N 17); and () normal controls.monitoring gas chromatography negative ion chemical
ionization/mass spectrometry. Samples were analyzed as
the pentafluorobenzyl ester trimethysilyl ether deriva-
tives monitoring the M-181 ions, m/z 569 for endogenous sis session (246  20 pg/mL) was not significantly differ-
F2-isoprostanes, and m/z 573 for [2H4]-8-iso-PGF2. The ent from normal controls (252  28 pg/mL, P  NS).
F2-isoprostanes elute as a series of chromatographic The kinetics of oxidation of plasma lipids obtained
peaks over 20 seconds, and quantification is based on before hemodialysis by SIN-1 was studied in 17 out of the
the primary peak that coelutes with the deuterated 8-iso- 23 patients with ESRD and 13 healthy control subjects.
PGF2 internal standard. All results were calculated by Addition of SIN-1 to plasma caused a time-dependent
reference to the deuterated 8-iso-PGF2 internal stan- increase in total F2-isoprostanes over 6 hours (Fig. 1).
dard. The interassay coefficient of variation of this proce- Pilot studies, in which the formation of total F2-isopros-
dure is 7%. tanes was followed up for up to 24 hours, did not show
any further increment beyond that observed at 6 hoursMeasurement of plasma uric acid and
(data not shown). Despite the absence of any differences- and -tocopherol
in the basal concentration of total F2-isoprostanes be-Uric acid levels (mol/L) were determined by reverse-
tween controls and patients with ESRD, the SIN-1–
phase high-performance liquid chromatography (HPLC)
induced formation of F2-isoprostanes at 6 hours was ap-coupled with electrochemical detection [21]. Plasma vita-
proximately doubled in ESRD patients (1861  174min E (- and 	-tocopherol) concentrations were quanti-
pg/mL vs. 987 54 pg/mL; P 0.0001) (Fig. 1). This dem-fied by HPLC assay [22]. Absolute vitamin E levels were
onstrates that plasma lipids from patients with ESRDcorrected for plasma triglyceride concentrations (mol/
are more susceptible to oxidation by SIN-1. Having es-mmol triglyceride).
tablished the time course for these reactions in vitro,
subsequent studies simply compared the concentrationStatistical analyses
of total F2-isoprostanes (at t 0 hour) to those generatedAll results are expressed as mean  SEM. Data was
by SIN-1 at 6 hours.analyzed using the Wilcoxon signed-rank test for paired
nonparametric data. Multiple comparisons were com-
Effect of hemodialysis on oxidizibility of plasma lipidspared by analysis of variance (ANOVA). Differences
To assess the effect of dialysis on the oxidizibility ofwere considered statistically significant if the P value
plasma lipids, blood was collected before and within 5was 0.05.
minutes of the end of a hemodialysis session, and the
SIN-1–induced formation of F2-isoprostanes from plasma
RESULTS lipids determined at 6 hours in 23 patients with ESRD.
Oxidizibility of plasma lipids in controls and Following dialysis, the basal concentration of total F2-iso-
patients with ESRD prostanes was 236  14 pg/mL, and this was not signifi-
cantly different from predialysis concentrations (246 The baseline biochemistry and hematology data in the
20 pg/mL). However, the hemodialysis procedure mark-patients with ESRD are shown in Table 1. The concen-
edly enhanced the SIN-1–induced formation of F2-iso-tration of total F2-isoprostanes in plasma taken from the
23 patients with ESRD immediately before a hemodialy- prostanes, with peak levels increasing from 1841  166
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Fig. 2. Plasma F2-isoprostane concentrations before () and after ( )
6 hours of 3-morpholino-sydnonimine (SIN-1)–mediated in vitro oxida-
tion of plasma samples from control human volunteers (N  13) and
end-stage renal disease (ESRD) patients before and after hemodialysis
(N 23). Values are mean SEM. *P 0.001 control vs. before dialysis.
Fig. 4. Consumption of uric acid (A ) and -tocopherol (B ) in whole
plasma during oxidation by 1 mmol/L 3-morpholino-sydnonimine (SIN-1).Fig. 3. 3-morpholino-sydnonimine (SIN-1) generated levels of F2-iso-
Data (mean  SEM) are expressed as nmol of uric acid or vitamin Eprostanes (F2-IsoPs) (at 6 hours) in plasma from patients before ()
consumed per minute. The samples from normal controls (), patientsand after ( ) hemodialysis. Dialysis membranes were divided into
before dialysis ( ), and patients after dialysis ( ) are shown. ** Signifi-biocompatible and bioincompatible. In both groups there was a signifi-
cantly different from control values (ANOVA, P  0.05).cantly enhanced generation of F2-isoprostanes by SIN-1 after dialysis
compared with predialysis values. ** Significantly different (P  0.01)
from baseline (prehemodialysis) levels. However, there was no signifi-
cant difference between the two types of membrane used in this study.
determined in a subgroup of four patients before and
after hemodialysis and in four healthy controls. Basal uric
acid levels were higher in patients with ESRD (361 pg/mL to 2437  168 pg/mL; P  0.001 (Fig. 2) in the
17 mol/L) compared with healthy controls (210  2923 subjects studied.
mol/L; P  0.01), consistent with a decreased renal
Effect of dialysis membrane on the oxidizibility of elimination of uric acid in the ESRD group. Plasma uric
plasma lipids acid decreased following hemodialysis (361 17 mol/L
to 123  21 mol/L, P  0.01). Addition of SIN-1 toThe oxidizibility of plasma lipids was compared in the
plasma resulted in the net consumption of uric acid,two groups of patients undergoing dialysis with either
although there were no differences between the amountsynthetic (N  10) or cellulosic membranes (N  13).
of uric acid consumed when ESRD and controls or be-As shown in Figure 3, there was no significant difference
fore and after dialysis specimens were compared (Fig. 4A).between the two types of membranes used (P  NS).
The interpretation of vitamin E (as -tocopherol) con-
Effect of SIN-1 on plasma urate and centration in plasma is complicated by differences in
tocopherol concentrations plasma lipid levels and by the acute hemoconcentration
that occurs with plasma solutes that are not filtered dur-The effect of SIN-1 oxidation on plasma concentra-
tions of uric acid, as well as - and 	-tocopherol was ing hemodialysis. Plasma vitamin E levels were signifi-
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cantly decreased in ESRD patients after correction for tween patients with chronic renal failure and controls
led us to develop a new method to assess the oxidizibilitytriglyceride concentration compared to normal controls,
but there was no significant change in vitamin E levels of plasma lipids with SIN-1 in ESRD patients. This method
measures oxidative stress under basal conditions in vivobefore and after dialysis. The vitamin E concentrations
were ESRD, before hemodialysis, 12  2 mol/mmol as determined by basal plasma total F2-isoprostanes, and
then quantitates the generation of F2-isoprostanes intriglyceride; after hemodialysis, 15  2 mol/mmol try-
glyceride; and controls, 34  6 mol/mmol triglyceride. vitro after stressing plasma lipids by the addition of the
peroxynitrite generator SIN-1.Following the addition of SIN-1 to plasma there was
a time-dependent consumption of vitamin E. This was There was no difference between basal plasma F2-iso-
prostanes in patients with ESRD or controls, and plasmaminimal in the plasma of normal controls over the 6-hour
incubation with SIN-1 (Fig. 4B). However, a marked levels did not increase after hemodialysis. This was a
surprising observation since it was recently reported inconsumption of vitamin E in plasma was observed after
2 hours of incubation with SIN-1. The consumption of a definitive study by Handelman et al [25] that basal
esterified F2-isoprostanes were increased by sixfold invitamin E was enhanced further in the plasma of patients
immediately following hemodialysis and was consistent patients undergoing regular intermittent hemodialysis
[25], but that a single episode of hemodilaysis did notwith increased oxidation of plasma lipids as evidenced
in Figure 2. significantly enhance the formation of esterified F2-iso-
prostanes. We did, however, observe a significant in-The basal plasma concentration of 	-tocopherol was
1.4 0.3mol/L in normal controls and 1.7 0.3mol/L crease in the oxidizibility of plasma lipids by peroxyni-
trite in patients with ESRD, and this effect was enhancedand 2.3  0.5 mol/L in patients before and after hemo-
dialysis, respectively. There were no significant changes by hemodialysis. Thus, our data suggest that there is
increased consumption of plasma antioxidants, and arein plasma concentrations of 	-tocopherol during the
6-hour incubation with SIN-1, which remained at over consistent with the presence of oxidative stress in pa-
tients with ESRD, which is enhanced by hemodialysis.90% of its basal levels in both patients and controls (data
One alternative possibility is that an altered lipid profilenot shown).
in the patients with chronic renal failure could increase
the levels of the substrate for SIN-1–induced oxidation,
DISCUSSION namely arachidonic acid. However, several studies have
The aim of this study was to measure basal oxidative consistently shown that patients with chronic renal fail-
stress in patients with ESRD undergoing hemodialysis ure, including those on hemodialysis, exhibit a signifi-
and to assess whether hemodialysis causes further oxida- cantly lower plasma concentration of arachidonic acid
tive injury. At present it is not clear whether the measure- [26–28] suggesting that this is not the mechanism for
ment of free or esterified F2-isoprostanes represents the increased F2-isoprostane generation by SIN-1. Moreover,
best marker for systemic oxidative stress in vivo. Most the observation that the oxidation of plasma lipids was
studies have used measurement of free F2-isoprostanes enhanced further following hemodialysis is consistent
[23, 24]. However, decreased elimination of free F2-iso- with consumption or depletion of endogenous antioxi-
prostanes due to chronic renal failure, or enhanced re- dants. The explanation for the discrepancy between our
moval or generation during hemodialysis, makes the as- data, and that published by Handelman et al [25] may
sessment of lipid peroxidation in ESRD more difficult. lie in fundamental differences of clinical practice be-
In a pilot study, we measured the plasma concentrations tween the United States and Europe, in terms of vascular
of free F2-isoprostanes in 26 patients with chronic renal access and the reuse of dialyzers. Many patients in the
failure patients who did not require hemodialysis. There study by Handelman et al [25] were dialyzed through
was a modest but significant increase in plasma free central venous access catheters and had an elevated
F2-isoprostanes in patients with chronic renal failure C-reactive protein (CRP), suggesting chronic inflamma-
compared to controls (chronic renal failure 35 5 pg/mL tion. It is not stated whether the dialysis membranes
vs. control 20  2 pg/mL, P  0.01). The advantage of were reused, but this is standard practice in many dialysis
measuring esterified F2-isoprostanes is that the problem units in the United States. In the current study, all pa-
of renal elimination is excluded. However, dynamic tients were dialyzed through native arteriovenous fistu-
changes, such as those that may be generated during las, and with single use dialysis membranes, and Euro-
hemodialysis, may occur too slowly to detect immedi- pean Pharmacopoiea Standard dialysate water. There
ately at the end of the dialysis session, since lipid peroxi- are some data to suggest that reusing dialysis membranes
dation commences with initiation of oxidation followed may be associated with an increased risk of cardiac mor-
by propagation, and this process takes a few hours in tality, and other studies have shown a strong correlation
vitro. Our initial observation that only modest differ- between increased CRP levels and cardiac deaths [29].
Indeed, Handelman et al [25] showed a positive correla-ences of plasma-free F2-isoprostanes were observed be-
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tion between CRP levels and basal F2-isoprostane con- in bioincompatible materials. Free radicals may be gen-
erated by leukocyte activation, due to membrane and/orcentrations. This suggests that chronic inflammation leads
to oxidative stress in ESRD. In the present study, we dialysate interactions, contaminated dialysate, mechani-
cal stress induced by peristaltic pumps, chemical stimulidid not measure the CRP levels at the time of blood
collection. However, on reviewing the routine monthly induced by the uremic environment, and abrupt changes
in pH and solute concentrations associated with hemodi-CRP data available from 13 of the patients in this study,
we observed a median concentration of CRP of 6.5 mg/L alysis [34]. Moreover, during hemodialysis, the release of
proinflammatory cytokines and chemotactic factors may(normal range,10 mg/L). Both interleukin-6 (IL-6) and
tumor necrosis factor- (TNF-) were also measured activate leukocytes and the endothelium. Thus, chronic
(ELISA) in these patients at around the time when these hemodialysis patients may be at increased risk of free
patients were studied. The median concentrations of IL-6 radical–mediated injury. This may be important in the
and TNF- were 3.3 pg/mL (normal range, 3.1 pg/mL) development and subsequent progression of cardiovas-
and 15.9 pg/mL (normal range, 15.6 pg/mL), respec- cular complications. In particular, LDL lipids might be at
tively. Therefore, the absence of chronic inflammation risk of oxidation when exposed to a high flux of reactive
in our patient population may be the major reason why oxygen or nitrogen species as observed in the subendo-
there was no overt basal oxidative stress in our patient thelium during the genesis of the atherosclerotic plaque.
group compared to our controls. Several groups have been interested in the relative oxida-
The key observation in our present study is that even tive stress imposed by different membranes used in
though basal concentrations of total F2-isoprostanes in chronic hemodialysis [35]. Although it was not a primary
patients with ESRD were not significantly different from aim of this study to compare the effect of different types
healthy controls, subtle differences in endogenous de- of dialyzer membranes on SIN-1–induced oxidation of
fenses against oxidative stress could be revealed by plasma lipids, we were not able to demonstrate any statis-
stressing the plasma lipids with peroxynitrite, using the tically significant difference between synthetic and cellu-
peroxynitrite generator SIN-1 [30]. One of the key ad- losic-based membranes. However, F2-isoprostane gener-
vantages of this method is that it evaluates the oxidizibil- ation was slightly greater, in particular following dialysis,
ity of plasma lipids without the need to separate and iso- in those patients who used the cellulosic membranes.
late LDL, for in vitro studies. In a recent study, Thomas, This study has highlighted a new approach to assess
Davies, and Stocker [31] exposed human plasma from the oxidizibility of plasma lipids. In our method we used
normal subjects to 5 mmol/L SIN-1 and also observed a the water-soluble SIN-1 because it produces species
minimal consumption of -tocopherol and urate over (namely, O •2 and NO • further reacting to form ONOO)
the first 6 hours of incubation. In the present study, there that are likely to be important factors in LDL oxidation
was an increased consumption of vitamin E, while uric in the subendothelium [36]. Moreover, we chose to assess
acid consumption was minimal. Thomas, Davies, and lipid oxidizibility in whole plasma instead of its subfrac-
Stocker also observed a rapid consumption of ascorbate, tions since it characterizes the oxidizibility of all plasma
bilirubin, and ubiquinol-10. Although plasma ascorbate lipoproteins in their biologic milieu rather than just one
concentrations were not measured in the current study, lipoprotein class in a buffer system. The study of the
previous investigations have shown that plasma ascor- oxidizibility of plasma represents a valid approach to ex
bate concentrations in patients with ESRD before hemo- vivo evaluation of the risk of lipid peroxidation in health
dialysis are decreased by about 50% compared to control and disease. This method has wide applicability, is readily
values, and this decreases by a further 50% after hemo- reproducible, and will help to assess therapeutic strategies
dialysis [12]. Other studies have suggested that plasma aimed to prevent lipid peroxidation during hemodialysis
concentrations of other antioxidants (such as thiols, sele- and the development of cardiovascular disease.
nium, glutathione peroxidase, and coenzyme Q10) are also
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